Registry of Cardiovascular Disease Patients
Launched by MACCABI HEALTHCARE SERVICES, ISRAEL · Dec 27, 2012
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The registry was initiated in 1998 by Maccabi Healthcare services, which is the second largest publicly funded HMO in Israel,serving 24% of the total population with a nationwide distribution.
The registry uses advanced information technology that integrates personal computerized community and hospital records, data from laboratory tests, dispensed medications, physiological signals, radiological images, and reports from investigations and procedures.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * Clinical Diagnosis of the following:
- • Ischemic Heart Disease,MI,non-MI,congestive heart failure,peripheral vascular disease, cerebrovascular disease CVA,TIA,patients with first AMI diagnosis from community physicians if they were hospitalized for lasting at least 3 days during a 30-day period prior to diagnosis.
- • Patients with prior coronary artery bypass grafting(CABG) or percutaneous coronary intervention (PCI), using relevant Current Procedural Terminology (CPT) codes
- Exclusion Criteria:
- • patients who were diagnosed as suffering from CHD by primary physician or general hospitals prior to 2000 with no further indication
- • Patients whose primary physician reported that the patient is CHD-free providing adequate medical records
About Maccabi Healthcare Services, Israel
Maccabi Healthcare Services, one of Israel's leading health maintenance organizations, is dedicated to advancing healthcare through innovative clinical research and trials. With a robust network of healthcare professionals and state-of-the-art facilities, Maccabi fosters a patient-centered approach, ensuring high-quality care and ethical standards in all research activities. The organization is committed to enhancing treatment options and improving patient outcomes by actively contributing to medical knowledge and evidence-based practices in various therapeutic areas. Through collaboration with academic institutions and industry partners, Maccabi aims to drive the future of healthcare in Israel and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tel Aviv, , Israel
Patients applied
Trial Officials
Gabriel Chodick, PHD
Study Director
Head,Epidemiology & Database Reseaech Unit, Medical Division, Maccabi H.S
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials